

BY E-MAIL

March 16, 2023

BSE Ltd. Phiroze Jeejeebhoy Towers 27 th Floor, Dalal Street Mumbai 400 023 E-mail: corp.relations@bseindia.com	The National Stock Exchange of India Ltd. Exchange Plaza, 5 th Flr, Plot # C/1 G Block, Bandra-Kurla Complex, Bandra (E), Mumbai 400 051. E-mail : takeover@nse.co.in
--	--

Dear Sir,

Re: Declaration under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011


Pursuant to Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, we are enclosing herewith our disclosure for allotment to us of 20,00,000 equity shares of Rs.10/- each of M/s. Lyka Labs Limited (BSE Scrip Code : 500259 / NSE Scrip Code : LYKALABS) @ Rs. 139.50 per share allotted to us on 15th March, 2023 on preferential basis.

Lyka Labs Limited has also allotted to us 50,00,000 warrants, each warrant convertible into 1(one) equity share of Lyka Labs Limited @ Rs. 139.50 per share, within a period of 18 months from the date of allotment of warrants at the option of allottee.

Kindly acknowledge the receipt.

Thanking you

Yours faithfully
For and on behalf Ipca Laboratories Limited



Harish P. Kamath
Company Secretary

Encl: a/a

Cc: Lyka Labs Ltd.
4801/B & 4802/A, GIDC Industrial Estate,
Ankleshwar – 393 002, Gujarat
E-mail id : companysecretary@lykalabs.com

Ipca Laboratories Ltd.
www.ipca.com

Format for disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Part A – Details of Acquisition

Name of the Target Company (TC)	Lyka Labs Limited (BSE Scrip Code : 500259 / NSE Scrip Code : LYKALABS)		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the Acquirer	Acquirer Ipca Laboratories Limited Person Acting in Concert Mr. Pranay Godha Mrs. Neetu Godha Mrs. Usha Godha Mrs. Bhawna Godha Mr. Premchand Godha		
Whether the acquirer belongs to Promoter / Promoter Group	Yes. Acquirer belongs to Promoter / Promoter Group		
Name(s) of the Stock Exchange(s) where the shares of TC are listed	BSE Ltd. (BSE); and The National Stock Exchange of India Ltd. (NSE)		
Details of the acquisition as follows	Number	% w.r.t total share / voting capital wherever applicable (*)	% w.r.t. total diluted share / voting capital of the TC (**)
Before the acquisition under consideration, holding of acquirer along with PACs of:			
a. Shares carrying voting rights			
i. Ipca Laboratories Ltd.	76,24,923	26.58%	26.58%
ii. Mr. Pranay Godha	3,00,000	1.05%	1.05%
iii. Mrs. Neetu Godha	10,000	0.03%	0.03%
iv. Mrs. Usha Godha	10,686	0.04%	0.04%
v. Mrs. Bhawna Godha	6,000	0.02%	0.02%
vi. Mr. Premchand Godha	10,900	0.04%	0.04%
TOTAL	79,62,509	27.76%	27.76%
b. Shares in the nature of encumbrance (pledge/lien/non-disposal undertaking/others)	Nil	Nil	Nil
c. Voting rights (VR) otherwise than by equity shares	Nil	Nil	Nil
d. Warrants / convertible securities / any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	Nil	Nil	Nil
e. Total (a+b+c+d)	79,62,509	27.76%	27.76%



Ipca Laboratories Ltd.
www.ipca.com

Details of the acquisition as follows	Number	% w.r.t total share / voting capital wherever applicable (*)	% w.r.t. total diluted share / voting capital of the TC (**)
Details of Acquisition / Sale			
a. Shares carrying voting rights acquired			
i. Ipca Laboratories Ltd.	20,00,000	6.52%	6.52%
b. VRs acquired otherwise than by equity shares	Nil	Nil	Nil
c. Warrants / Convertible securities / any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired	50,00,000**	**	**
d. Shares in the nature of encumbrance (pledge/lien/non-disposal undertaking/others)	Nil	Nil	Nil
e. Total (a+b+c+/-d)	20,00,000	6.52%	6.52%
After the acquisition, holding of			
a. Shares carrying voting rights			
i. Ipca Laboratories Ltd.	96,24,923	31.36%	31.36%
ii. Mr. Pranay Godha	3,00,000	0.98%	0.98%
iii. Mrs. Neetu Godha	10,000	0.03%	0.03%
iv. Mrs. Usha Godha	10,686	0.03%	0.03%
v. Mrs. Bhawna Godha	6,000	0.02%	0.02%
vi. Mr. Premchand Godha	10,900	0.04%	0.04%
TOTAL	99,62,509	32.46%	32.46%
b. VRs otherwise than by equity shares	Nil	Nil	Nil
c. Warrants / convertible securities / any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	50,00,000**	**	**
d. Shares in the nature of encumbrance (pledge/lien/non-disposal undertaking/others)	Nil	Nil	Nil
e. Total (a+b+c+d)	99,62,509	32.46%	32.46%
Mode of acquisition (eg. Open market / public issue/rights issue/preferential allotment/inter-se transfer etc.)	Preferential Allotment		
Date of acquisition of shares or date of receipt of intimation of allotment of shares/VR/warrants/convertible securities/any other instrument that entitles the acquirer to receive shares in the TC	15 th March, 2023		



Ipca Laboratories Ltd.
www.ipca.com

125, Kandivli Industrial Estate, CTS No. 328, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6210 5000 F: +91 22 6210 5005
Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6647 4444


E: ipca@ipca.com CIN: L24239MH1949PLC007837

Equity share capital/total voting capital of the TC before the said acquisition	2,86,90,000	100%	100%
Equity share capital /total voting capital of the TC after the said acquisition	3,06,90,000	100%	100%
Total diluted share/voting capital of the TC after the said acquisition (considering balance outstanding convertible warrants)	3,56,90,000	100%	100%

** Pursuant to the necessary special resolution passed by its members, M/s. Lyka Labs Limited has also allotted 50,00,000 convertible warrants to the Company at its board meeting held on 15th March, 2023. Each warrant allotted is convertible into one equity share of Rs. 10/- each of M/s. Lyka Labs Limited @ Rs. 139.50 per share within a period of 18 months from the date of allotment, at the option of the allottee, either wholly or in tranches. As and when the equity shares of said company are allotted to us upon conversion of warrants, the necessary disclosure for its pre and post holding of equity shares in the said company will be made by us under the provisions of Regulation 29(2) of SEBI (SAST) Regulations, 2011.

Signature of the acquirer / Authorised Signatory:

For Ipca Laboratories Ltd.



Harish P. Kamath
Company Secretary

Place: Mumbai

Date: 16th March, 2023